Author: Chang Chen; Jianying Huang; Zhenshun Cheng; Jianyuan Wu; Song Chen; Yongxi Zhang; Bo Chen; Mengxin Lu; Yongwen Luo; Jingyi Zhang; Ping Yin; Xinghuan Wang
Title: Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial Document date: 2020_3_20
ID: 14he8n3u_13
Snippet: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.17.20037432 doi: medRxiv preprint 9 critical COVID-19 patients were performed according to the Chinese guideline. 11 After enrollment, blood biochemistry, urinalysis, coagulation function, C-reactive protein and SARS-CoV-2 nucleic acid were examined on the third (D3±1 day) and the seventh day (D7±2 day) with additional chest CT on the s.....
Document: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.17.20037432 doi: medRxiv preprint 9 critical COVID-19 patients were performed according to the Chinese guideline. 11 After enrollment, blood biochemistry, urinalysis, coagulation function, C-reactive protein and SARS-CoV-2 nucleic acid were examined on the third (D3±1 day) and the seventh day (D7±2 day) with additional chest CT on the seventh day. The axillary temperature, respiratory rate, oxygen saturation without supportive oxygen, usage of oxygen therapy and noninvasive positive pressure ventilation (NPPV) were recorded in daily follow-up. Repeated measurements were made at least twice in each follow-up. The measurements were taken after 15 minutes rest at room temperature (23±2°C). Adverse events and concomitant medication were observed.
Search related documents:
Co phrase search for related documents- adverse event and concomitant medication: 1, 2, 3, 4
- blood biochemistry and coagulation function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Co phrase search for related documents, hyperlinks ordered by date